U.S. Compounding Pharmacies Market Forecasts - 2034

U.S. Compounding Pharmacies Market - By Pharmacy Type, By Sterility, By Product, By Compounding Type, By Application, By Therapeutic Area - Forecast, 2025 - 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Global

1.3.2&nbsp;&nbsp;&nbsp; Regional/Country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 360&deg; synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Zonal

2.2.2&nbsp;&nbsp;&nbsp; Pharmacy type

2.2.3&nbsp;&nbsp;&nbsp; Sterility

2.2.4&nbsp;&nbsp;&nbsp; Product

2.2.5&nbsp;&nbsp;&nbsp; Compounding type

2.2.6&nbsp;&nbsp;&nbsp; Therapeutic area

2.2.7&nbsp;&nbsp;&nbsp; Application

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.1.1&nbsp;&nbsp;&nbsp; Supplier landscape

3.1.2&nbsp;&nbsp;&nbsp; Value addition at each stage

3.1.3&nbsp;&nbsp;&nbsp; Factor affecting the value chain

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing geriatric population and improved longevity

3.2.1.2&nbsp;&nbsp;&nbsp; Growing acceptance of personalized medicines in the U.S.

3.2.1.3&nbsp;&nbsp;&nbsp; Increasing drug shortage

3.2.1.4&nbsp;&nbsp;&nbsp; Convenience of using compounded drugs

3.2.1.5&nbsp;&nbsp;&nbsp; Growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Issues related to safety standards of compounded drugs

3.2.2.2&nbsp;&nbsp;&nbsp; Changing regulatory scenario

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Expanding veterinary compounding

3.2.3.2&nbsp;&nbsp;&nbsp; Advancements in delivery technologies

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Reimbursement landscape

3.6&nbsp;&nbsp;&nbsp; Innovative compounding technologies

3.6.1&nbsp;&nbsp;&nbsp; Web-based quality management system

3.6.2&nbsp;&nbsp;&nbsp; Digital tools

3.7&nbsp;&nbsp;&nbsp; Future market trends

3.8&nbsp;&nbsp;&nbsp; Consumer behaviour analysis

3.9&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.10&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Mergers and acquisitions

4.6.2&nbsp;&nbsp;&nbsp; Partnerships and collaborations

4.6.3&nbsp;&nbsp;&nbsp; New product launches

4.6.4&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Pharmacy Type, 2021 &ndash; 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; 503A

5.3&nbsp;&nbsp;&nbsp; 503B

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Sterility, 2021 &ndash; 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Sterile

6.3&nbsp;&nbsp;&nbsp; Non-sterile

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 &ndash; 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Oral

7.2.1&nbsp;&nbsp;&nbsp; Solid preparations

7.2.1.1&nbsp;&nbsp;&nbsp; Tablets

7.2.1.2&nbsp;&nbsp;&nbsp; Capsules

7.2.1.3&nbsp;&nbsp;&nbsp; Granules

7.2.1.4&nbsp;&nbsp;&nbsp; Powder

7.2.1.5&nbsp;&nbsp;&nbsp; Other solid preparations

7.2.2&nbsp;&nbsp;&nbsp; Liquid preparations

7.2.2.1&nbsp;&nbsp;&nbsp; Solutions

7.2.2.2&nbsp;&nbsp;&nbsp; Suspension

7.2.2.3&nbsp;&nbsp;&nbsp; Emulsion

7.2.2.4&nbsp;&nbsp;&nbsp; Syrup

7.2.2.5&nbsp;&nbsp;&nbsp; Other liquid preparations

7.3&nbsp;&nbsp;&nbsp; Topical

7.3.1&nbsp;&nbsp;&nbsp; Ointments

7.3.2&nbsp;&nbsp;&nbsp; Creams

7.3.3&nbsp;&nbsp;&nbsp; Gels

7.3.4&nbsp;&nbsp;&nbsp; Pastes

7.3.5&nbsp;&nbsp;&nbsp; Other topical products

7.4&nbsp;&nbsp;&nbsp; Rectal

7.4.1&nbsp;&nbsp;&nbsp; Suppositories

7.4.2&nbsp;&nbsp;&nbsp; Enema

7.4.3&nbsp;&nbsp;&nbsp; Other rectal products

7.5&nbsp;&nbsp;&nbsp; Parenteral

7.5.1&nbsp;&nbsp;&nbsp; Large volume parenterals (LVPs)

7.5.2&nbsp;&nbsp;&nbsp; Small volume parenterals (LVPs)

7.6&nbsp;&nbsp;&nbsp; Nasal

7.7&nbsp;&nbsp;&nbsp; Ophthalmic

7.8&nbsp;&nbsp;&nbsp; Otic

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Compounding Type, 2021 &ndash; 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Pharmaceutical ingredient alteration (PIA)

8.3&nbsp;&nbsp;&nbsp; Currently unavailable pharmaceutical manufacturing (CUPM)

8.4&nbsp;&nbsp;&nbsp; Pharmaceutical dosage alteration (PDA)

8.5&nbsp;&nbsp;&nbsp; Other compounding types

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &ndash; 2034 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Adult

9.3&nbsp;&nbsp;&nbsp; Geriatric

9.4&nbsp;&nbsp;&nbsp; Veterinary

9.5&nbsp;&nbsp;&nbsp; Pediatric

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Therapeutic Area, 2021 &ndash; 2034 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; Pain management

10.3&nbsp;&nbsp;&nbsp; Hormone replacement

10.4&nbsp;&nbsp;&nbsp; Dermatology

10.5&nbsp;&nbsp;&nbsp; Specialty drugs

10.6&nbsp;&nbsp;&nbsp; Nutritional supplements

10.7&nbsp;&nbsp;&nbsp; Other therapeutic areas

Chapter 11&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Zone, 2021 &ndash; 2034 ($ Mn)

11.1&nbsp;&nbsp;&nbsp; Key trends

11.2&nbsp;&nbsp;&nbsp; Northeast

11.2.1&nbsp;&nbsp;&nbsp;Connecticut

11.2.2&nbsp;&nbsp;&nbsp;Maine

11.2.3&nbsp;&nbsp;&nbsp;Massachusetts

11.2.4&nbsp;&nbsp;&nbsp;New Hampshire

11.2.5&nbsp;&nbsp;&nbsp;Rhode Island

11.2.6&nbsp;&nbsp;&nbsp;Vermont

11.2.7&nbsp;&nbsp;&nbsp;New Jersey

11.2.8&nbsp;&nbsp;&nbsp;New York

11.2.9&nbsp;&nbsp;&nbsp;Pennsylvania

11.3&nbsp;&nbsp;&nbsp; East North Central

11.3.1&nbsp;&nbsp;&nbsp;Wisconsin

11.3.2&nbsp;&nbsp;&nbsp;Michigan

11.3.3&nbsp;&nbsp;&nbsp;Illinois

11.3.4&nbsp;&nbsp;&nbsp;Indiana

11.3.5&nbsp;&nbsp;&nbsp;Ohio

11.4&nbsp;&nbsp;&nbsp; West North Central

11.4.1&nbsp;&nbsp;&nbsp;North Dakota

11.4.2&nbsp;&nbsp;&nbsp;South Dakota

11.4.3&nbsp;&nbsp;&nbsp;Nebraska

11.4.4&nbsp;&nbsp;&nbsp;Kansas

11.4.5&nbsp;&nbsp;&nbsp;Minnesota

11.4.6&nbsp;&nbsp;&nbsp;Iowa

11.4.7&nbsp;&nbsp;&nbsp;Missouri

11.5&nbsp;&nbsp;&nbsp; South Atlantic

11.5.1&nbsp;&nbsp;&nbsp;Delaware

11.5.2&nbsp;&nbsp;&nbsp;Maryland

11.5.3&nbsp;&nbsp;&nbsp;District of Columbia

11.5.4&nbsp;&nbsp;&nbsp;Virginia

11.5.5&nbsp;&nbsp;&nbsp;West Virginia

11.5.6&nbsp;&nbsp;&nbsp;North Carolina

11.5.7&nbsp;&nbsp;&nbsp;South Carolina

11.5.8&nbsp;&nbsp;&nbsp;Georgia

11.5.9&nbsp;&nbsp;&nbsp;Florida

11.6&nbsp;&nbsp;&nbsp; East South Central

11.6.1&nbsp;&nbsp;&nbsp;Kentucky

11.6.2&nbsp;&nbsp;&nbsp;Tennessee

11.6.3&nbsp;&nbsp;&nbsp;Mississippi

11.6.4&nbsp;&nbsp;&nbsp;Alabama

11.7&nbsp;&nbsp;&nbsp; West South Central

11.7.1&nbsp;&nbsp;&nbsp;Oklahoma

11.7.2&nbsp;&nbsp;&nbsp;Texas

11.7.3&nbsp;&nbsp;&nbsp;Arkansas

11.7.4&nbsp;&nbsp;&nbsp;Louisiana

11.8&nbsp;&nbsp;&nbsp; Mountain States

11.8.1&nbsp;&nbsp;&nbsp;Idaho

11.8.2&nbsp;&nbsp;&nbsp;Montana

11.8.3&nbsp;&nbsp;&nbsp;Wyoming

11.8.4&nbsp;&nbsp;&nbsp;Nevada

11.8.5&nbsp;&nbsp;&nbsp;Utah

11.8.6&nbsp;&nbsp;&nbsp;Colorado

11.8.7&nbsp;&nbsp;&nbsp;Arizona

11.8.8&nbsp;&nbsp;&nbsp;New Mexico

11.9&nbsp;&nbsp;&nbsp; Pacific Central

11.9.1&nbsp;&nbsp;&nbsp;California

11.9.2&nbsp;&nbsp;&nbsp;Alaska

11.9.3&nbsp;&nbsp;&nbsp;Hawaii

11.9.4&nbsp;&nbsp;&nbsp;Oregon

11.9.5&nbsp;&nbsp;&nbsp;Washington

Chapter 12&nbsp;&nbsp;&nbsp;Company Profiles

12.1&nbsp;&nbsp;&nbsp; Baxter International

12.2&nbsp;&nbsp;&nbsp; B. Braun

12.3&nbsp;&nbsp;&nbsp; Dougherty&#39;s Pharmacy

12.4&nbsp;&nbsp;&nbsp; Fagron

12.5&nbsp;&nbsp;&nbsp; Fresenius Kabi

12.6&nbsp;&nbsp;&nbsp; Harrow

12.7&nbsp;&nbsp;&nbsp; Institutional Pharmacy Solutions

12.8&nbsp;&nbsp;&nbsp; ITC Compounding Pharmacy

12.9&nbsp;&nbsp;&nbsp; McGuff Outsourcing Solutions

12.10&nbsp;&nbsp;&nbsp; Nephron Pharmaceuticals

12.11&nbsp;&nbsp;&nbsp; Pavilion Compounding Pharmacy

12.12&nbsp;&nbsp;&nbsp; Pencol Compounding Pharmacy

12.13&nbsp;&nbsp;&nbsp; QuVa Pharma

12.14&nbsp;&nbsp;&nbsp; Rx3 Compounding Pharmacy

12.15&nbsp;&nbsp;&nbsp; Triangle Compounding Pharmacies

12.16&nbsp;&nbsp;&nbsp; Village Compounding Pharmacy

12.17&nbsp;&nbsp;&nbsp; Wedgewood Pharmacy

&nbsp;&nbsp;&nbsp;

U.S. Compounding Pharmacies Market

Inquiry Before Buying